We divided the study patients into three groups based on the purpose and timing of KL-6 measurement: differentiating between pneumonia and ILD (category 1), diagnosing and assessing the severity of suspicious ILD (category 2), and evaluating the baseline level before initiating cancer treatment such as RT or ICI administration (category 3). Here, MUC1 is linked to cancer.